Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Infection kinetics of human adenovirus serotype 41 in HEK 293 cells

Full text
Author(s):
Siqueira-Silva, Joselma [1] ; Yeda, Fernanda Perez [1] ; Favier, Anne-Laure [2] ; Mezin, Paulette [3] ; Silva, Misael Leonardo [1] ; Barrella, Karina Medici [1] ; Mehnert, Dolores Ursula [1] ; Fender, Pascal [2] ; Harsi, Charlotte Marianna [1]
Total Authors: 9
Affiliation:
[1] Univ Sao Paulo, Lab Biol Mol Adenovirus, Dept Microbiol, Inst Ciencias Biomed, BR-05508900 Sao Paulo - Brazil
[2] Inst Biol Struct Jean Pierre Ebel, Grenoble - France
[3] CHU Grenoble, La Tronche - France
Total Affiliations: 3
Document type: Journal article
Source: Memórias do Instituto Oswaldo Cruz; v. 104, n. 5, p. 736-744, AUG 2009.
Web of Science Citations: 10
Abstract

The purpose of this work was to acquire an overview of the infectious cycle of HAdV-41 in permissive HEK 293 cells and compare it to that observed with the prototype of the genus, Human adenovirus C HAdV-2. HEK 293 cells were infected with each virus separately and were harvested every 12 h for seven days. Infection kinetics were analysed using confocal and electronic microscopy. The results show that, when properly cultivated, HAdV-41 was not fastidious. It had a longer multiplication cycle, which resulted in the release of complete viral particles and viral stocks reached high titres. After 60 h of infection, the export of viral proteins from the infected cell to the extracellular milieu was observed, with a pattern similar to that previously described for HAdV-2 penton-base trafficking after 30 h of infection. HAdV-41 had a non-lytic cycle and the infection spread from the first infected cell to its neighbours. The release process of the viral particles is unknown. The results observed for HAdV-41 infection in HEK 293 cells show how different this virus is from the prototype HAdV-2 and provides information for the development of this vector for use in gene therapy. (AU)